Nusinersen also effective in Patients with Type 2 and 3 spinal Muscular Atrophy

被引：0
|
作者：
Krome, Susanne
机构：
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2019年 / 87卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [21] Impact of nusinersen on respiratory progression in paediatric patients with spinal muscular atrophy type 2 and non-ambulant type 3
    Trucco, F.
    Weststrate, H.
    Ridout, D.
    Scoto, M.
    Rohwer, A.
    Coratti, G.
    Main, M.
    Pane, M.
    Messina, S.
    D'Amico, A.
    Bruno, C.
    De Vivo, D.
    Darras, B.
    Day, J.
    Baranello, G.
    Sansona, V.
    Bertini, E.
    Finkel, R.
    Mercuri, E.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S89 - S89
  • [22] Scoliosis in Spinal muscular atrophy type I in the nusinersen era
    Al Amrani, F.
    Amin, R.
    Chiang, J.
    Boyd, J.
    Vajsar, J.
    Dowling, J.
    Gonorazky, H.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S73 - S73
  • [23] Nusinersen for the treatment of spinal muscular atrophy
    Chiriboga, Claudia A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (10) : 955 - 962
  • [24] Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
    Al Amrani, Fatima
    Amin, Reshma
    Chiang, Jackie
    Xiao, Lena
    Boyd, Jennifer
    Law, Eugenia
    Nigro, Elisa
    Weinstock, Lauren
    Stosic, Ana
    Gonorazky, Hernan D.
    NEUROLOGY-CLINICAL PRACTICE, 2022, 12 (04) : 279 - 287
  • [25] Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
    Faravelli, Irene
    Meneri, Megi
    Saccomanno, Domenica
    Velardo, Daniele
    Abati, Elena
    Gagliardi, Delia
    Parente, Valeria
    Petrozzi, Lucia
    Ronchi, Dario
    Stocchetti, Nino
    Calderini, Edoardo
    D'Angelo, Grazia
    Chidini, Giovanna
    Prandi, Edi
    Ricci, Giulia
    Siciliano, Gabriele
    Bresolin, Nereo
    Comi, Giacomo Pietro
    Corti, Stefania
    Magri, Francesca
    Govoni, Alessandra
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (05) : 3034 - 3039
  • [26] Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy
    Waldrop, M.
    Lowes, L.
    Toops, J.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Kotha, K.
    Paul, G.
    Moore-Clingenpeel, M.
    Tsao, C.
    Noritz, G.
    Shell, R.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S188 - S188
  • [27] Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen
    Cebulla, Gina
    Hai, Ling
    Warnken, Uwe
    Guengoer, Cansu
    Hoffmann, Dirk C.
    Korporal-Kuhnke, Mirjam
    Wildemann, Brigitte
    Wick, Wolfgang
    Kessler, Tobias
    Weiler, Markus
    JOURNAL OF NEUROLOGY, 2025, 272 (04)
  • [28] Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients
    Szabo, Lena
    Gergely, Anita
    Jakus, Rita
    Fogarasi, Andras
    Grosz, Zoltan
    Molnar, Maria Judit
    Andor, Ildiko
    Schulcz, Orsolya
    Goschler, Adam
    Medveczky, Erika
    Czovek, Dorottya
    Herczegfalvi, Agnes
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2020, 27 : 37 - 42
  • [29] A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3
    Cote, Isabelle
    Hodgkinson, Victoria
    Nury, Marianne
    Bastenier-Boutin, Louis
    Rodrigue, Xavier
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2025, 52 (01) : 119 - 128
  • [30] Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
    Becker, Lena-Luise
    Weiss, Claudia
    Guenther, Rene
    Hermann, Andreas
    Theophil, Manuela
    Huebner, Angela
    Smitka, Martin
    von der Hagen, Maja
    Kaindl, Angela M.
    JOURNAL OF PEDIATRIC NEUROLOGY, 2022, 20 (04) : 252 - 257
12345